CCL22 and neoplasm: Overexpression of CXCL2 or CCL22, or depletion of CD8a, impaired ttIL-12’s efficacy in suppressing tumor growth and metastasis, which validated the novel mechanism of ttIL-12 in converting a short OS immune profile to a long OS immune profile.